NCI and Rockland Have Added New Antibodies to Thriving Collaboration Portfolio:
The National Cancer Institute (NCI) has partnered with Rockland Immunochemicals to develop, in conjunction with the NCI’s Center for Cancer Research (CCR), nearly 100 antibodies involved in signal transduction and cancer research.
Since 2011, Rockland and CCR have been providing you with high-quality monoclonal and polyclonal antibodies. The portfolio is expanding rapidly as better reagents are being developed. To date, Rockland has successfully developed and delivered over 150 antibodies to investigators and released the majority to the market. Collaborations are ongoing, and new products are continually being added and put through rigorous rounds of testing.
Learn more about the NCI and Rockland Collaboration.